SCHEMBL10985672

SCHEMBL10985672

Oc1nsnc1-c1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GCGR P47871 1/20 0.38
ALOX5 P09917 2/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.35
PTPN11 Q06124 1/20 0.35
PTGDR2 Q9Y5Y4 3/20 0.35
CYP1A2 P05177 2/20 0.34
ERBB2 P04626 1/20 0.34
CDH1 P12830 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15850505 0.84 KDM4E (0.45) KDM4ELMNAGAAL3MBTL1GCGR
SCHEMBL30704329 0.79 ALOX5 (0.39) KDM4ELMNAGCGRALOX5NPC1
SCHEMBL30704358 0.79 ALOX15 (0.37) KDM4EGAAGCGRNPC1RAB9A
SCHEMBL17922820 0.79 AHR (0.46) KDM4EGAAL3MBTL1NPC1RAB9A
SCHEMBL8935466 0.78 KDM4E (0.41) KDM4ELMNAGAAL3MBTL1GCGR
SCHEMBL9451310 0.78 MEN1 (0.41) KDM4ELMNAGAAL3MBTL1ALOX5
SCHEMBL8935457 0.75 NPC1 (0.45) KDM4ELMNAGAAL3MBTL1NPC1
SCHEMBL30704313 0.75 KMT2A (0.47) KDM4ELMNANPC1RAB9AALDH1A1
SCHEMBL30704314 0.75 ALDH1A1 (0.49) KDM4ELMNAGAAL3MBTL1ALOX5
SCHEMBL8519653 0.73 CA12 (0.46) KDM4ELMNAGAAL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117327029-A Azole derivative and preparation method thereof 云南大学 2024-01-02 CN disclosed
US-9649300-B2 Inhibition of WNT, TGF beta and Hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-05-16 US disclosed
US-20160200697-A1 INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS University of Pittsburgh - of the Commonwealth Sys tem of Higher Education (US) 2016-07-14 US disclosed
US-4555521-A Nematicidal 3-substituted-4-phenyl-1,2,5-thiadiazoles FMC CORPORATION (US) 1985-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200697-A1 INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS WNT1, YAP1, CTNNB1 KDM4E 2007/4885LMNA 3828/4885GAA 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.